Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    Contact Supplier

    Menu

    Pegcetacoplan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apellis, Sobi Report Ph3 Data For EMPAVELI In C3G, IC-MPGN
    Apellis, Sobi Report Ph3 Data For EMPAVELI In C3G, IC-MPGN

    06 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/06/3095128/0/en/Apellis-and-Sobi-Announce-EMPAVELI-pegcetacoplan-Showed-Sustained-Efficacy-at-One-Year-in-Phase-3-Study-for-C3G-and-Primary-IC-MPGN.html

    GLOBENEWSWIRE
    06 Jun 2025
    Share Share
    Sobi's Aspaveli® 52-week Phase 3 Valiant Data in Nephrology
    Sobi's Aspaveli® 52-week Phase 3 Valiant Data in Nephrology

    03 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/invitation-sobis-aspaveli---52-week-phase-3-valiant-data-in-nephrology-302471733.html

    PR NEWSWIRE
    03 Jun 2025
    Share Share
    Apellis' Syfovre faces tough road ahead in GA market
    Apellis' Syfovre faces tough road ahead in GA market

    14 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/apellis-weak-syfovre-quarter-signals-uphill-climb-geographic-atrophy-med-mizuho

    FIERCE PHARMA
    14 May 2025
    Share Share
    Apellis' Empaveli for C3G and IC-MPGN Gets FDA Priority Review
    Apellis' Empaveli for C3G and IC-MPGN Gets FDA Priority Review

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053146/0/en/Apellis-Announces-FDA-Acceptance-and-Priority-Review-of-the-Supplemental-New-Drug-Application-for-EMPAVELI-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share
    Apellis, Sobi’s Aspaveli Gets EMA Validate For C3G & IC-MPGN Expansion
    Apellis, Sobi’s Aspaveli Gets EMA Validate For C3G & IC-MPGN Expansion

    20 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/20/3029307/0/en/Apellis-and-Sobi-Announce-EMA-Validation-of-Indication-Extension-Application-for-Aspaveli-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html

    GLOBENEWSWIRE
    20 Feb 2025
    Share Share
    EMA Validates Aspaveli Indication Extension For C3G & IC-MPGN
    EMA Validates Aspaveli Indication Extension For C3G & IC-MPGN

    20 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ema-validates-indication-extension-application-for-aspaveli-for-treatment-of-c3g-and-primary-ic-mpgn-302381200.html

    PR NEWSWIRE
    20 Feb 2025
    Share Share